Abstract
LNMRI has sought to develop a methodology for the identification and accurate detection of impurities emitting gamma radiation at the metrological level, aiming to meet the recommendations not only of the international pharmacopoeia, but also of CNEN and ANVISA regarding quality control that can ensure patients That the doses received by the practices are as low as practicable. As an initial goal, it was possible to obtain an efficiency curve with uncertainty around 1% necessary to start future measurements of interest applied to nuclear medicine and to begin the development of the impurities analysis technique.
Highlights
Radiopharmaceuticals are preparations consisting of one or more radionuclides and a pharmacological moiety
It is important that purity checks be continued over time for the entire working life of a reference source or even a radiopharmaceutical administered to the patient, since the impurities of long half-lives have a longer life and their Percentage of the radionuclides with short half-lives, as is the case with radiopharmaceuticals
The radiopharmaceutical is characterized by a short half-life, but in this mode of production the presence of radionuclide impurities, usually of larger half-lives in relation to the main one, is common
Summary
Radiopharmaceuticals are preparations consisting of one or more radionuclides and a pharmacological moiety. Would it be a secondary standardization laboratory that would be assigned to measure or verify more than activity and impurity, and would normally be measured with calibrated equipment using activity standards provided by national laboratories via gamma spectrometry methods; Purity (chemical and radionuclide) should be the responsibility of the producing center and nuclear data are generally produced by specialized national metrology laboratories with their decay parameters related to radionuclides published in updated tables of nuclear data Thinking in this light, the LNMRI has sought to develop a methodology for analyzing these impurities in order to have as an end product an internal document where concepts for approaching the subject are well delineated. It is necessary to develop a procedure using gamma spectrometry techniques to ensure that these limits set by the pharmacopoeia are not exceeded [4..10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
